Literature DB >> 9563074

Stability of alkoxycarbonylamidine prodrugs.

Z Shahrokh1, E Lee, A G Olivero, R A Matamoros, K D Robarge, A Lee, K J Weise, B K Blackburn, M F Powell.   

Abstract

PURPOSE: Alkoxycarbonylamidine prodrug modification was used to mask the positively-charged amidine moiety of an Arg-Gly-Asp peptidomimetic and enhance oral bioavailability. The aqueous stability of ethoxycarbonylamidine (ECA), ethanethiocarbonylamidine (ETCA) and phenoxycarbonylamidine (PCA) prodrugs was examined.
METHODS: Degradation was followed by RP-HPLC and rate constants were determined from a degradation scheme defined by product analysis.
RESULTS: ECA gave a pH of maximum stability at pH approximately 7 and was independent of pH below pH approximately 4. A novel degradation pathway of ECA, conversion to ethoxycarbonyl- aminocarbonyl, was observed below pH 7. The relative rates below pH 7 were ECA approximately ETCA < PCA, in the same order of decreasing pKa of the conjugate acid of the substituted amidino group. Base-catalyzed cleavage of ECA to yield the amidine derivative gave the relative rates ECA < ETCA < PCA, in agreement with the decreasing pKa of the leaving groups.
CONCLUSIONS: The observed rate constants at all pHs were small enough that only 5-30% (depending on the substituent) undesirable degradation is predicted during transit time of the gut. The spontaneous post-absorptive conversion to the amidine drugs at neutral pH is predicted to be 6x greater for the PCA than the ECA prodrugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563074     DOI: 10.1023/a:1011928415808

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  RATES OF HYDROLYSIS OF CARBAMATE AND CARBONATE ESTERS IN ALKALINE SOLUTION.

Authors:  L W DITTERT; T HIGUCHI
Journal:  J Pharm Sci       Date:  1963-09       Impact factor: 3.534

Review 2.  Prodrug strategies based on intramolecular cyclization reactions.

Authors:  D Shan; M G Nicolaou; R T Borchardt; B Wang
Journal:  J Pharm Sci       Date:  1997-07       Impact factor: 3.534

Review 3.  Gastrointestinal absorption II. Formulation factors affecting drug bioavailability.

Authors:  J Blanchard
Journal:  Am J Pharm Sci Support Public Health       Date:  1978 Sep-Oct

4.  In vitro and in vivo hydrolysis of 4-benzoylphenyl N-methylcarbamate.

Authors:  L W Brown; A A Forist
Journal:  J Pharm Sci       Date:  1973-01       Impact factor: 3.534

Review 5.  Minireview: nucleotide prodrugs.

Authors:  R J Jones; N Bischofberger
Journal:  Antiviral Res       Date:  1995-05       Impact factor: 5.970

6.  Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.

Authors:  T Weller; L Alig; M Beresini; B Blackburn; S Bunting; P Hadváry; M H Müller; D Knopp; B Levet-Trafit; M T Lipari; N B Modi; M Müller; C J Refino; M Schmitt; P Schönholzer; S Weiss; B Steiner
Journal:  J Med Chem       Date:  1996-08-02       Impact factor: 7.446

7.  Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.

Authors:  T Yasuda; H K Gold; C Kohmura; L Guerrero; H Yaoita; J T Fallon; S Bunting; D Collen
Journal:  Arterioscler Thromb       Date:  1993-05

8.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-07       Impact factor: 91.245

9.  Pilocarpine prodrugs. II. Synthesis, stability, bioconversion, and physicochemical properties of sequentially labile pilocarpine acid diesters.

Authors:  H Bundgaard; E Falch; C Larsen; G L Mosher; T J Mikkelson
Journal:  J Pharm Sci       Date:  1986-08       Impact factor: 3.534

10.  (Acyloxy)alkyl carbamate prodrugs of norfloxacin.

Authors:  J Alexander; R A Fromtling; J A Bland; B A Pelak; E C Gilfillan
Journal:  J Med Chem       Date:  1991-01       Impact factor: 7.446

View more
  1 in total

1.  Prodrug approach for alphaIIbbeta3-peptidomimetic antagonists to enhance their transport in monolayers of a human intestinal cell line (Caco-2): comparison of in vitro and in vivo data.

Authors:  W Kamm; P Raddatz; J Gante; T Kissel
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.